Company / R&D per Share
BeOne Medicines Ltd. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.55
FY2025
5-year range
$1.21 / $1.55
FY2021-FY2025
Trend
+7.7%
vs FY2024
Sector context
#123 of 208
Health Care
What the data says
At $1.55, BeOne Medicines Ltd.'s r&d per share ranks #123 of 208 in the Health Care sector. R&D per Share has increased for 4 consecutive years, from $1.21 in FY2021 to $1.55 in FY2025.
Based on SEC 10-K filings.
1.55 in FY2025 with a 5-year CAGR of -0.9%.
Improved from $1.31 to $1.55 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +8.0%
- 5-Year CAGR
- -0.9%
- 10-Year CAGR
- -
Sector benchmark
#123 of 208 in Health CareTop 59% of 208This company $1.55 Sector average $12.19
▼
-87.3% below sector average
Key checks
Key Insights
- BeOne Medicines Ltd.'s r&d per share has grown for 4 consecutive years.
- In FY2025, r&d per share increased 7.7% year-over-year.
- Ranks #123 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.55 | +7.7% |
| FY2024 | $1.44 | +9.5% |
| FY2023 | $1.31 | +6.7% |
| FY2022 | $1.23 | +1.6% |
| FY2021 | $1.21 | -25.1% |
| FY2020 | $1.62 | +35.3% |
| FY2019 | $1.19 | +4.2% |
| FY2018 | $1.15 | +119.9% |
| FY2017 | $0.52 | -38.2% |
| FY2016 | $0.84 | +60.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026